These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15033141)

  • 41. Experimental models of Parkinson's disease.
    Beal MF
    Nat Rev Neurosci; 2001 May; 2(5):325-34. PubMed ID: 11331916
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
    Kotzbauer PT; Giasson BI; Kravitz AV; Golbe LI; Mark MH; Trojanowski JQ; Lee VM
    Exp Neurol; 2004 Jun; 187(2):279-88. PubMed ID: 15144854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progressive supranuclear palsy and corticobasal degeneration: lumping versus splitting.
    Scaravilli T; Tolosa E; Ferrer I
    Mov Disord; 2005 Aug; 20 Suppl 12():S21-8. PubMed ID: 16092076
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tau gene mutations and their effects.
    Goedert M
    Mov Disord; 2005 Aug; 20 Suppl 12():S45-52. PubMed ID: 16092090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
    Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS
    Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. alpha-Synuclein-immunoreactive structure formation is enhanced in sympathetic ganglia of patients with multiple system atrophy.
    Sone M; Yoshida M; Hashizume Y; Hishikawa N; Sobue G
    Acta Neuropathol; 2005 Jul; 110(1):19-26. PubMed ID: 15895299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunohistochemical localization of NUB1, a synphilin-1-binding protein, in neurodegenerative disorders.
    Tanji K; Mori F; Kakita A; Zhang H; Kito K; Kamitani T; Takahashi H; Wakabayashi K
    Acta Neuropathol; 2007 Oct; 114(4):365-71. PubMed ID: 17549501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease.
    Mamah CE; Lesnick TG; Lincoln SJ; Strain KJ; de Andrade M; Bower JH; Ahlskog JE; Rocca WA; Farrer MJ; Maraganore DM
    Ann Neurol; 2005 Mar; 57(3):439-43. PubMed ID: 15732111
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH; Uversky VN; Munishkina LA; Fink AL; Halfter W; Cole GJ
    Glycobiology; 2005 Dec; 15(12):1320-31. PubMed ID: 16037493
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathogenic effects of alpha-synuclein aggregation.
    Lundvig D; Lindersson E; Jensen PH
    Brain Res Mol Brain Res; 2005 Mar; 134(1):3-17. PubMed ID: 15790525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology.
    Wszolek ZK; Pfeiffer RF; Tsuboi Y; Uitti RJ; McComb RD; Stoessl AJ; Strongosky AJ; Zimprich A; Müller-Myhsok B; Farrer MJ; Gasser T; Calne DB; Dickson DW
    Neurology; 2004 May; 62(9):1619-22. PubMed ID: 15136696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
    Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
    Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Large French-Canadian family with Lewy body parkinsonism: exclusion of known loci.
    Grimes DA; Grimes JD; Racacho L; Scoggan KA; Han F; Schwarz BA; Woulfe J; Bulman D
    Mov Disord; 2002 Nov; 17(6):1205-12. PubMed ID: 12465058
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
    Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
    Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. REM sleep behaviour disorder: how useful is it for the differential diagnosis of parkinsonism?
    Munhoz RP; Teive HA
    Clin Neurol Neurosurg; 2014 Dec; 127():71-4. PubMed ID: 25459246
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
    Hauser MA; Li YJ; Xu H; Noureddine MA; Shao YS; Gullans SR; Scherzer CR; Jensen RV; McLaurin AC; Gibson JR; Scott BL; Jewett RM; Stenger JE; Schmechel DE; Hulette CM; Vance JM
    Arch Neurol; 2005 Jun; 62(6):917-21. PubMed ID: 15956162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of the protein disulfide isomerase family member PDIp in experimental Parkinson's disease and Lewy body pathology.
    Conn KJ; Gao W; McKee A; Lan MS; Ullman MD; Eisenhauer PB; Fine RE; Wells JM
    Brain Res; 2004 Oct; 1022(1-2):164-72. PubMed ID: 15353226
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia.
    Parkkinen L; Kauppinen T; Pirttilä T; Autere JM; Alafuzoff I
    Ann Neurol; 2005 Jan; 57(1):82-91. PubMed ID: 15562510
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aggregation of neurofilament and alpha-synuclein proteins in Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia.
    Trojanowski JQ; Lee VM
    Arch Neurol; 1998 Feb; 55(2):151-2. PubMed ID: 9482355
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.